Aligos Therapeutics Inc (ALGS)

NASD · Healthcare · Biotechnology · USA

Aligos Therapeutics Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.

Aligos Therapeutics is a clinical-stage biotechnology company developing drug candidates for liver diseases and viral infections. Its current pipeline includes pevifoscorvir sodium for chronic hepatitis B, ALG-055009 for metabolic dysfunction-associated steatohepatitis and obesity, and ALG-097558 for coronavirus infections, along with preclinical programs targeting these therapeutic areas.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Aligos Therapeutics Inc stock.

Our verdict on ALGS

Undervalued: intrinsic value $6.79 per share, market price $1.36, margin of safety 80.0% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $6.79; the price of $1.36 is 80% below that value.

ETFs with the most weight in ALGS

4 more funds hold it; the full list is part of the paid plan.

More on ALGS

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Is ALGS undervalued or overvalued?

ALGS is undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $6.79; the price of $1.36 is 80% below that value.

What is the intrinsic value of ALGS?

$6.79 per share (as of the 2026-11-17 close), against a market price of $1.36. That is a margin of safety of 80.0%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.